Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

The European challenges of funding orphan medicinal products

10 references·1 citing·37 second hop

FromToDepth

this work references cited by second hop

References

1984Official Journal of the European Communities4,027 cited
2007Assessing the economic challenges posed by orphan drugs279 cited
2011Pricing and reimbursement of orphan drugs: the need for more transparency261 cited
2012Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?171 cited
2011Estimating the budget impact of orphan medicines in Europe: 2010 - 2020133 cited
2018Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group131 cited
2013Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries122 cited
2012What Is Wrong with Orphan Drug Policies?110 cited
2017Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)103 cited
2016Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries67 cited

Cited by

2021How to Value Orphan Drugs? A Review of European Value Assessment Frameworks62 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work